MedWatch

Strong interest in Swedish biotech IPO

Investors have expressed strong interest in participating in the upcoming IPO of Swedish Ascelia Pharma, but CEO Magnus Corfitzen denies that the company has sold itself too cheap.

Foto: Colourbox

Swedish biotech company Ascelia Pharma, led by Danish Magnus Corfitzen, experienced great support from investors interested in buying shares in the company, when it goes public on Nasdaq Stockholm on March 13.

According to the company, the share issue in connection with the IPO was "significantly oversubscribed" when it ended Monday this week. However, the firm does not elaborate further on this statement.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier